1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Microglia promote glioblastoma via mTOR‐mediated immunosuppression of the tumour microenvironment

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Tumour‐associated microglia/macrophages ( TAM) are the most numerous non‐neoplastic populations in the tumour microenvironment in glioblastoma multiforme ( GBM), the most common malignant brain tumour in adulthood. The mTOR pathway, an important regulator of cell survival/proliferation, is upregulated in GBM, but little is known about the potential role of this pathway in TAM. Here, we show that GBM‐initiating cells induce mTOR signalling in the microglia but not bone marrow‐derived macrophages in both in vitro and in vivo GBM mouse models. mTOR‐dependent regulation of STAT3 and NF‐κB activity promotes an immunosuppressive microglial phenotype. This hinders effector T‐cell infiltration, proliferation and immune reactivity, thereby contributing to tumour immune evasion and promoting tumour growth in mouse models. The translational value of our results is demonstrated in whole transcriptome datasets of human GBM and in a novel in vitro model, whereby expanded‐potential stem cells ( EPSC)‐derived microglia‐like cells are conditioned by syngeneic patient‐derived GBM‐initiating cells. These results raise the possibility that microglia could be the primary target of mTOR inhibition, rather than the intrinsic tumour cells in GBM.

          Abstract

          GBM‐induced stromal mTORC1 mediates immune evasion by shifting inflammatory cytokine secretion.

          Related collections

          Most cited references54

          • Record: found
          • Abstract: found
          • Article: not found

          mTOR kinase structure, mechanism and regulation by the rapamycin-binding domain

          The mammalian target of rapamycin (mTOR), a phosphoinositide 3-kinase related protein kinase, controls cell growth in response to nutrients and growth factors and is frequently deregulated in cancer. Here we report co-crystal structures of a truncated mTOR-mLST8 complex with an ATP transition state mimic and with ATP-site inhibitors. The structures reveal an intrinsically active kinase conformation, with catalytic residues and mechanism remarkably similar to canonical protein kinases. The active site is highly recessed due to the FKBP12-Rapamycin binding (FRB) domain and an inhibitory helix protruding from the catalytic cleft. mTOR activating mutations map to the structural framework that holds these elements in place, indicating the kinase is controlled by restricted access. In vitro biochemistry indicates that the FRB domain acts as a gatekeeper, with its rapamycin-binding site interacting with substrates to grant them access to the restricted active site. FKBP12-rapamycin inhibits by directly blocking substrate recruitment and by further restricting active site access. The structures also reveal active site residues and conformational changes that underlie inhibitor potency and specificity.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            GlioVis data portal for visualization and analysis of brain tumor expression datasets

              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Challenges to curing primary brain tumours

              Despite decades of research, brain tumours remain among the deadliest of all forms of cancer. The ability of these tumours to resist almost all conventional and novel treatments relates, in part, to the unique cell-intrinsic and microenvironmental properties of neural tissues. In an attempt to encourage progress in our understanding and ability to successfully treat patients with brain tumours, Cancer Research UK convened an international panel of clinicians and laboratory-based scientists to identify challenges that must be overcome if we are to cure all patients with a brain tumour. The seven key challenges summarized in this Position Paper are intended to serve as foci for future research and investment.
                Bookmark

                Author and article information

                Contributors
                s.marino@qmul.ac.uk
                Journal
                EMBO J
                EMBO J
                10.1002/(ISSN)1460-2075
                EMBJ
                embojnl
                The EMBO Journal
                John Wiley and Sons Inc. (Hoboken )
                0261-4189
                1460-2075
                22 June 2020
                03 August 2020
                22 June 2020
                : 39
                : 15 ( doiID: 10.1002/embj.v39.15 )
                : e103790
                Affiliations
                [ 1 ] Blizard Institute Barts and The London School of Medicine and Dentistry Queen Mary University London London UK
                [ 2 ] National Hospital for Neurology and Neurosurgery University College London Hospitals NHS Foundation Trust London UK
                [ 3 ] Division of Neuropathology Department of Neurodegenerative Disease UCL Queen Square Institute of Neurology London UK
                [ 4 ] Department of Neurosurgery The University of Texas MD Anderson Cancer Center Houston TX USA
                [ 5 ] Human Oncology and Pathogenesis Program Memorial Sloan Kettering Cancer Center New York NY USA
                [ 6 ] Department of Oncology Ludwig Institute for Cancer Research University of Lausanne Lausanne Switzerland
                Author notes
                [*] [* ]Corresponding author. Tel:+44 2078 822585; E‐mail: s.marino@ 123456qmul.ac.uk
                Author information
                https://orcid.org/0000-0001-9067-1796
                https://orcid.org/0000-0002-9821-0342
                https://orcid.org/0000-0002-9612-2883
                Article
                EMBJ2019103790
                10.15252/embj.2019103790
                7396846
                32567735
                9f209c10-91f1-4e60-8cbe-63dcec47f7b8
                © 2020 The Authors. Published under the terms of the CC BY 4.0 license

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 20 October 2019
                : 03 May 2020
                : 08 May 2020
                Page count
                Figures: 12, Tables: 0, Pages: 21, Words: 16857
                Funding
                Funded by: Brain Tumour Research
                Funded by: Barts Charity
                Funded by: Willoughby Trustees
                Funded by: Swiss Cancer League
                Funded by: The Brain Tumour Charity
                Categories
                Article
                Articles
                Custom metadata
                2.0
                03 August 2020
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.6 mode:remove_FC converted:03.08.2020

                Molecular biology
                glioblastoma,microglia,mtor,t cells,tam,cancer,immunology
                Molecular biology
                glioblastoma, microglia, mtor, t cells, tam, cancer, immunology

                Comments

                Comment on this article